Literature DB >> 22079388

Thalassaemia in pregnancy.

Tak Yeung Leung1, Terence T Lao.   

Abstract

Thalassaemia is the most common monogenetic disease worldwide. Antenatal screening is effective and simple, and accurate genetic prenatal diagnosis can be achieved in early gestation. Less invasive methods are feasible with ultrasound fetal assessment for alpha-thalassaemia, analysis of circulating fetal nucleic acid in maternal plasma, and pre-implantation genetic diagnosis. Women with thalassaemia major and intermedia are at risk of various maternal complications, such as cardiac failure, alloimmunisation, viral infection, thrombosis, endocrine and bone disturbances. Therefore, it is prudent to adhere to a standard management plan in this group of pregnant women. Close monitoring of the maternal and fetal condition during pregnancy is essential, and various treatments, such as blood transfusion or postpartum prophylaxis for thromboembolism, may be indicated. After birth, resumption of iron chelation and bisphosphonates treatment is needed, and counselling on breast feeding and contraception should be given.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22079388     DOI: 10.1016/j.bpobgyn.2011.10.009

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  12 in total

1.  Pregnancy Outcomes in Women with Homozygous Beta Thalassaemia: A single-centre experience from Oman.

Authors:  Nihal Al-Riyami; Maha Al-Khaduri; Shahina Daar
Journal:  Sultan Qaboos Univ Med J       Date:  2014-07-24

2.  Therapeutic effect of Colla corii asini on improving anemia and hemoglobin compositions in pregnant women with thalassemia.

Authors:  Yanfang Li; Hui He; Lilin Yang; Xiangyi Li; Daocheng Li; Songping Luo
Journal:  Int J Hematol       Date:  2016-07-25       Impact factor: 2.490

3.  An evaluation of thyroid autoimmunity in patients with beta thalassemia minor: A case-control study.

Authors:  Ali Ramazan Benli; Sati Sena Yildiz; Mehmet Ali Cikrikcioglu
Journal:  Pak J Med Sci       Date:  2017 Sep-Oct       Impact factor: 1.088

4.  Fertility in Patients with Thalassemia and Outcome of Pregnancies: A Turkish Experience

Authors:  Burcu Akıncı; Akkız Şahin Yaşar; Nihal Özdemir Karadaş; Zuhal Önder Siviş; Hamiyet Hekimci Özdemir; Deniz Yılmaz Karapınar; Can Balkan; Kaan Kavaklı; Yeşim Aydınok
Journal:  Turk J Haematol       Date:  2019-06-14       Impact factor: 1.831

5.  Ethnic and socioeconomic variation in cause-specific preterm infant mortality by gestational age at birth: national cohort study.

Authors:  Mary E Kroll; Jennifer J Kurinczuk; Jennifer Hollowell; Alison Macfarlane; Yangmei Li; Maria A Quigley
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2019-05-23       Impact factor: 5.747

6.  Validation of anaemia, haemorrhage and blood disorder reporting in hospital data in New South Wales, Australia.

Authors:  Heather J Baldwin; Tanya A Nippita; Siranda Torvaldsen; Therese M McGee; Kristen Rickard; Jillian A Patterson
Journal:  BMC Res Notes       Date:  2021-05-04

7.  Pregnancy with a severe hemoglobinopathy: unintended consequences of transfusions.

Authors:  David Kim; Hector Mendez-Figueroa; Brenna L Anderson
Journal:  Case Rep Obstet Gynecol       Date:  2013-01-27

8.  Pregnancy outcomes amongst thalassemia traits.

Authors:  Tharangrut Hanprasertpong; Ounjai Kor-anantakul; Roengsak Leetanaporn; Thitima Suntharasaj; Chitkasaem Suwanrath; Ninlapa Pruksanusak; Savitree Pranpanus
Journal:  Arch Gynecol Obstet       Date:  2013-05-17       Impact factor: 2.344

Review 9.  Pregnancy in women with thalassemia: challenges and solutions.

Authors:  George Petrakos; Panagiotis Andriopoulos; Maria Tsironi
Journal:  Int J Womens Health       Date:  2016-09-08

10.  Impact of the two-dose rubella vaccination regimen on incidence of rubella seronegativity in gravidae aged 25 years and younger.

Authors:  Shuk Yi Annie Hui; Daljit S Sahota; Terence T Lao
Journal:  PLoS One       Date:  2017-08-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.